Unknown

Dataset Information

0

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.


ABSTRACT: Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine.Thirty-one adults, 18-55 years, 20 naive and 11 prior rAd5 vaccine recipients were randomized to receive single rAd5 vaccine via needle or Biojector IM injection at 1010 PU in a Phase I open label clinical trial. Solicited reactogenicity was collected for 5 days; clinical safety and immunogenicity follow-up was continued for 24 weeks.Overall, injections by either method were well tolerated. There were no serious adverse events. Frequency of any local reactogenicity was 16/16 (100%) for Biojector compared to 11/15 (73%) for needle injections. There was no difference in HIV Env-specific antibody response between Biojector and needle delivery. Env-specific antibody responses were more than 10-fold higher in subjects receiving a booster dose of rAd5 vaccine than after a single dose delivered by either method regardless of interval between prime and boost.Biojector delivery did not improve antibody responses to the rAd5 vaccine compared to needle administration. Homologous boosting with rAd5 gene-based vectors can boost insert-specific antibody responses despite pre-existing vector-specific immunity.Clinicaltrials.gov NCT00709605 NCT00709605.

SUBMITTER: Sarwar UN 

PROVIDER: S-EPMC4179264 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

Sarwar Uzma N UN   Novik Laura L   Enama Mary E ME   Plummer Sarah A SA   Koup Richard A RA   Nason Martha C MC   Bailer Robert T RT   McDermott Adrian B AB   Roederer Mario M   Mascola John R JR   Ledgerwood Julie E JE   Graham Barney S BS  

PloS one 20140929 9


<h4>Background</h4>Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine.<h4>Methods</h4>Thirty-one adults, 18-55 years, 20 naive and 11 prior rAd5 vaccine recipients were randomized to receive single rAd5 vaccine via needle or Biojector IM injection at 1010 PU in a Phase I open label clinical trial. Solicited reactogenicity  ...[more]

Similar Datasets

| S-EPMC2947213 | biostudies-literature
| S-EPMC3732790 | biostudies-literature
| S-EPMC6629094 | biostudies-literature
| S-EPMC224991 | biostudies-other
| S-EPMC9226178 | biostudies-literature
| S-EPMC6711196 | biostudies-literature
| S-EPMC10291065 | biostudies-literature
| S-EPMC7881234 | biostudies-literature
| S-EPMC8684349 | biostudies-literature
| S-EPMC9394428 | biostudies-literature